MM-120 for Anxiety Disorders

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Cedar Clinical Research, Draper, UT
Anxiety Disorders+1 More
MM-120 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Eligible Conditions

  • Anxiety Disorders
  • Anxiety

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Anxiety Disorders

Study Objectives

0 Primary · 3 Secondary · Reporting Duration: 12 weeks

12 weeks
Assess the incidence of Adverse Events (AEs) and Serious Adverse Events (AEs)
Dose-Response
Improved Quality of Life as measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Anxiety Disorders

Trial Design

5 Treatment Groups

Arm 2- 25 μg MM-120
1 of 5
Arm 4- 100 μg MM-120
1 of 5
Arm 3- 50 μg MM-120
1 of 5
Arm 5- 200 μg MM-120
1 of 5
Arm 1- Placebo
1 of 5
Experimental Treatment
Non-Treatment Group

200 Total Participants · 5 Treatment Groups

Primary Treatment: MM-120 · Has Placebo Group · Phase 2

Arm 2- 25 μg MM-120
Drug
Experimental Group · 1 Intervention: MM-120 · Intervention Types: Drug
Arm 4- 100 μg MM-120
Drug
Experimental Group · 1 Intervention: MM-120 · Intervention Types: Drug
Arm 3- 50 μg MM-120
Drug
Experimental Group · 1 Intervention: MM-120 · Intervention Types: Drug
Arm 5- 200 μg MM-120
Drug
Experimental Group · 1 Intervention: MM-120 · Intervention Types: Drug
Arm 1- Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks
Closest Location: Cedar Clinical Research · Draper, UT
Photo of utah 1Photo of utah 2Photo of utah 3
2010First Recorded Clinical Trial
1 TrialsResearching Anxiety Disorders
2 CompletedClinical Trials

Who is running the clinical trial?

Mind Medicine, Inc.Lead Sponsor
2 Previous Clinical Trials
160 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of generalized anxiety disorder.
You are able to provide informed consent.
You have an acceptable overall medical condition to be safely enrolled into and to complete the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.